Clinical Ink Announces Addition of New Module to Their Lumenis™ eSource Ecosystem
WINSTON-SALEM, N.C.–(BUSINESS WIRE)–Clinical Ink, a global clinical trial technology company, announces the addition of a new component to their Lumenis™ eSource Ecosystem. With the addition of eConsent, Clinical Ink’s Lumenis platform expands further, providing purpose-built solutions for your protocol and anytime, anywhere access to study data. eConsent will join existing clinical modules including direct data…
Details